MacGuire Cheswick & Tuttle Investment Counsel’s Pacira BioSciences PCRX Stock Holding History

MacGuire Cheswick & Tuttle Investment Counsel’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,560	Closed	-$255K	–	90
2016 Q2	$255K	Hold	7,560	–	–	0.06%	77
2016 Q1	$401K	Buy	7,560 +525	+7%	+$30.7K	0.09%	67
2015 Q4	$540K	Sell	7,035 -1,175	-14%	-$66.5K	0.12%	66
2015 Q3	$337K	Sell	8,210 -400	-5%	-$24.5K	0.08%	78
2015 Q2	$609K	Hold	8,610	–	–	0.14%	68
2015 Q1	$765K	Buy	8,610 +500	+6%	+$50.7K	0.17%	66
2014 Q4	$719K	Buy	8,110 +3,025	+59%	+$286K	0.16%	68
2014 Q3	$493K	Hold	5,085	–	–	0.12%	72
2014 Q2	$467K	Buy	5,085 +575	+13%	+$43.8K	0.11%	71
2014 Q1	$316K	Buy	+4,510	New	+$307K	0.08%	77

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MacGuire Cheswick & Tuttle Investment Counsel's PCRX Position: Q3 2016 in Review

MacGuire Cheswick & Tuttle Investment Counsel sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 7,560 shares — an estimated $255K sold.

MacGuire Cheswick & Tuttle Investment Counsel first reported a position in PCRX in Q1 2014 and held it in 10 quarters. The position peaked at $765K in Q1 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

MacGuire Cheswick & Tuttle Investment Counsel reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
MacGuire Cheswick & Tuttle Investment Counsel sold 7,560 Pacira BioSciences shares in Q3 2016, an estimated $255K.
MacGuire Cheswick & Tuttle Investment Counsel first reported a position in Pacira BioSciences in Q1 2014 and held it in 10 quarters.
MacGuire Cheswick & Tuttle Investment Counsel's Pacira BioSciences position peaked at $765K in Q1 2015.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on MacGuire Cheswick & Tuttle Investment Counsel's 13F filing for Q3 2016, filed 3 Nov 2016.